{"id":"NCT00696436","sponsor":"Takeda","briefTitle":"An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.","officialTitle":"A Double-Blind, Randomized, Placebo-Controlled, 5-Arm Titration Study to Evaluate the Efficacy and Safety of TAK-491 When Compared With Valsartan and Olmesartan in Subjects With Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2008-06-12","resultsPosted":"2011-04-19","lastUpdate":"2011-04-19"},"enrollment":1291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Azilsartan medoxomil","otherNames":["TAK-491","Edarbi"]},{"type":"DRUG","name":"Valsartan","otherNames":["Diovan®"]},{"type":"DRUG","name":"Olmesartan","otherNames":["Benicar®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Azilsartan Medoxomil 40 mg QD","type":"EXPERIMENTAL"},{"label":"Azilsartan Medoxomil 80 mg QD","type":"EXPERIMENTAL"},{"label":"Valsartan 320 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Olmesartan 40 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Placebo QD","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to placebo, valsartan and olmesartan in participants with essential hypertension.","primaryOutcome":{"measure":"Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.","timeFrame":"Baseline and Week 6.","effectByArm":[{"arm":"Azilsartan Medoxomil 40 mg QD","deltaMin":-13.42,"sd":0.69},{"arm":"Azilsartan Medoxomil 80 mg QD","deltaMin":-14.53,"sd":0.702},{"arm":"Valsartan 320 mg QD","deltaMin":-10.22,"sd":0.696},{"arm":"Olmesartan 40 mg QD","deltaMin":-11.99,"sd":0.666},{"arm":"Placebo QD","deltaMin":-0.25,"sd":0.917}],"pValues":[{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG003","p":"0.009"},{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG003","p":"0.136"},{"comp":"OG000 vs OG002","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":131,"countries":["United States","Argentina","Brazil","Mexico","Peru","Puerto Rico"]},"refs":{"pmids":["21282560"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":280},"commonTop":["Headache"]}}